2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Endometrial Neoplasms
7
Lymphatic Metastasis
6
Uterine Cervical Neoplasms
5
Urinary Bladder Neoplasms
3
Breast Neoplasms
3
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Postoperative Complications
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphedema
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Clinical Stage I Gastric Cancer AJCC v8
2
Carcinoma, Transitional Cell
2
Vulvar Neoplasms
1
Uterine Neoplasms
1
Urologic Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Recurrence
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Platelet Glycoprotein IV Deficiency
1
Parotid Neoplasms
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Lymph Node Excision
×
Clear all
NCT03230201
2017-08-08
UTUC
Peking University First Hospital
Phase NA
Unknown
80 enrolled